Annual report pursuant to Section 13 and 15(d)

Other Intangible Assets

v3.19.1
Other Intangible Assets
 12 Months Ended
Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Other Intangible Assets

7. Other Intangible Assets

 

The net carrying value of the identifiable intangible assets as of December 31, 2018 and December 31, 2017 is as follows:

 

         

As of

December 31, 2018

    

As of

December 31, 2017

  
    Life     Carrying     Carrying  
    (Years)     Amount     Amount  
Diagnostic assets:                        
Asuragen acquisition:                        
Thyroid     9     $ 8,519     $ 8,519  
RedPath acquisition:                        
Pancreas test     7       16,141       16,141  
Barrett’s test     9       18,351       18,351  
Total           $ 43,011     $ 43,011  
Diagnostic lab:                        
CLIA Lab     2.3     $ 609     $ 609  
                         
Accumulated Amortization           $ (13,767 )   $ (10,515 )
                         
Net Carrying Value           $ 29,853     $ 33,105  

 

Amortization expense was approximately $3.3 million for the years ended December 31, 2018 and 2017, respectively. Estimated amortization expense for the next five years is as follows:

 

2019     2020     2021     2022     2023  
$ 3,252     $ 4,272     $ 4,908     $ 2,987     $ 2,987